Table 1.
Normal hamsters (J2N-n) | PBS treatment (J2N-k) | Low-dose liraglutide treatment (J2N-k) | High-dose liraglutide treatment (J2N-k) | |
---|---|---|---|---|
(n = 8) | (n = 14) | (n = 12) | (n = 13) | |
Biometry | ||||
Body weight, g | 120 ± 4.8 | 111 ± 2.7 | 113 ± 2.1 | 107 ± 2.8 |
Heart, g | 0.51 ± 0.22 | 0.63 ± 0.20 | 0.60 ± 0.02 | 0.72 ± 0.04 |
Heart/BW, mg/g | 4.3 ± 0.0 | 5.7 ± 0.2 | 5.3 ± 0.3 | 6.7 ± 0.4* |
Lungs, g | 0.75 ± 0.03 | 0.74 ± 0.04 | 0.62 ± 0.02 | 0.85 ± 0.09 |
Lungs/BW, mg/g | 5.8 ± 0.2 | 6.8 ± 0.4 | 5.5 ± 0.2 | 7.9 ± 0.9 |
Echocardiography | ||||
HR, beats/min | 392 ± 18 | 376 ± 13 | 412 ± 17 | 376 ± 19 |
LVEDD, mm | 4.5 ± 0.1 | 7.5 ± 0.2 | 7.5 ± 0.2 | 7.4 ± 0.1 |
LVESD, mm | 2.5 ± 0.1 | 6.6 ± 0.2 | 6.4 ± 0.2 | 6.3 ± 0.2 |
LV ejection, % | 0.81 ± 0.01 | 0.31 ± 0.01 | 0.36 ± 0.02 | 0.35 ± 0.02 |
LV FS, % | 0.45 ± 0.01 | 0.13 ± 0.01 | 0.15 ± 0.01 | 0.15 ± 0.01 |
LV AW, mm | 0.95 ± 0.02 | 0.81 ± 0.02 | 0.72 ± 0.02* | 0.67 ± 0.01* |
LV PW, mm | 1.02 ± 0.02 | 0.84 ± 0.02 | 0.81 ± 0.02 | 0.79 ± 0.02 |
Intracardiac pressure | ||||
Positive dP/dt, mmHg/s | 5512 ± 539 | 3566 ± 235 | 3100 ± 310 | 2501 ± 290* |
Negative dP/dt, mmHg/s | − 4119 ± 543 | − 2669 ± 143 | − 2425 ± 281 | − 1700 ± 171* |
EDP, mmHg | 8.65 ± 1.7 | 8.71 ± 2.4 | 12.5 ± 4.3 | 13.8 ± 2.8 |
Max pressure, mmHg | 132 ± 13 | 80.6 ± 4.2 | 81.9 ± 14 | 66.1 ± 5.5 |
Min pressure, mmHg | 4.5 ± 2.0 | 6.1 ± 2.0 | 9.3 ± 3.0 | 9.4 ± 2.0 |
All values are expressed as mean ± SEM
HR heart rate, LVEDD left ventricular end-diastolic diameter, LVESD left ventricular end-systolic diameter, FS fractional shortening, AW anterior wall, PW posterior wall, EDP end-diastolic pressure, FFA free fatty acid
Liraglutide treatment groups compared with the PBS treatment group by the step-down method. *P < 0.05